title: Dysautonomia syndrome in the acute recovery phase after traumatic brain injury: relief with intrathecal Baclofen therapy.
abstract: In the initial phase of severe head injury, dysautonomic abnormalities are frequent. Within the framework of a prospective study, evaluating the efficacy of continuous intrathecal Baclofen therapy (CIBT) on hypertonia during the initial recovery phase of severe head injury, the authors report on the preliminary results of this treatment on paroxysmal dysautonomia about four patients. Continuous intrathecal Baclofen infusion was first delivered, for a test period, continuously for 6 days. If a relapse of dysautonomia occurred at the end of the test period, an implantation of a continuous intrathecal infusion pump delivering Baclofen was performed. Results were assessed with four continuous variables; duration (days), dose of Baclofen per day (microg/d), number of dysautonomic paroxysmal episodes per day, and initial recovery evaluated by a scale of the first initial stages of head injury coma recovery. For three patients: (1) the number of dysautonomic paroxysmal episodes per day and the doses of Baclofen during the follow-up period were correlated (p = 0.02, p < 0.001, p = 0.008, respectively, distribution-free test of Spearman), (2) during the test period and the relapse after the test period, the number of paroxysmal episodes and the Baclofen dose are correlated to p < 0.05, p = 0.03, p = 0.04, respectively (distribution-free test of Spearman). The second statistical test was used to prove that Baclofen doses and number of paroxysmal dysautonomic episodes are correlated independently of the duration of follow-up. The fourth patient improved with CIBT without any recurrence at the end of the treatment test period. For the four patients, recovery score increased during the overall follow-up. In the authors' experience CIBT is very efficient to control paroxysmal dysautonomia during the initial recovery phase in severe head injury, and seems to facilitate recovery.
authors.affiliation: Clinique Universitaire de Neurochirurgie, Hôpital Pellegrin, Bordeaux, France. emmanuel.cuny@chu-bordeaux.fr
authors.forename: E
authors.initials: E
authors.lastname: Cuny
authors.forename: E
authors.initials: E
authors.lastname: Richer
authors.forename: J P
authors.initials: JP
authors.lastname: Castel
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001342:Autonomic Nervous System Diseases / Q000188:drug therapy* / Q000209:etiology; D001418:Baclofen / Q000008:administration & dosage / Q000627:therapeutic use*; D001930:Brain Injuries / Q000150:complications* / Q000503:physiopathology*; D018755:GABA Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D015600:Glasgow Coma Scale; D006801:Humans; D007278:Injections, Spinal; D008297:Male; D012074:Remission Induction
chemical_list: D018755:GABA Agonists; D001418:Baclofen